Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 13Head & Neck 12Genitourinary 10Gynecologic 8Endocrine 8Dermatologic 8Thoracic 7Tumor-Agnostic 6CNS 5Sarcoma 4Other solid neoplasm 3NET 3Lymphoid 2Breast 1

Conditions

Neuroendocrine Tumors 3Carcinoma, Neuroendocrine 1

Interventions

Everolimus 18lanreotide 7Octreotide 7pembrolizumab 6Sunitinib 6Magnetic Resonance Spectroscopy 5lutetium Lu 177 dotatate 4gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3pasireotide 3lenvatinib 3arginyllysine 3Temozolomide 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × lenvatinib × NET × Clear all
NCT04848337 2026-05-11

PLANE-PC

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
45 enrolled 8 charts
EndocrineNET

Neuroendocrine Tumors

NCT03290079 2025-12-22

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
20 enrolled 12 charts
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02678780 2025-07-24

TALENT

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
123 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡